Stratified probabilities. Probability of EFS and S stratified by BM, CNS, or BM/CNS (A) and response to COP reduction (B). (A) Product-limit estimate of probability of EFS in patients with BM disease only (BM⁺/CNS⁻), CNS disease only (BM⁻/CNS⁺), and combined BM and CNS disease (BM⁺/CNS⁺) (88% ± 3.0% versus 82 ± 5.6% versus 61% ± 6.0%, P < .001). (B) Product-limit estimate of probability of EFS in patients with complete response (CR; 100%), incomplete response (IR; 20%-99%) and nonresponse (NR; < 20%) after COP reduction therapy (94% ± 3.8% versus 78 ± 3.1% versus 30% ± 16%, P < .001).